pathophysiology of osteoporosis has

pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities, and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3) defective repair of microdamage from normal daily activities,. and (4) excessive bone remodeling rates. These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation, antiresorptives, mechanical loading, and disuse have helped further knowledge of the factors affecting bone quality and the mechanisms that underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

Pathophysiology of osteoporosis has evolved to include compromised bone strength and skeletal fragility caused by several. Factors: (1) defects in microarchitecture of trabeculae, (2) defective intrinsic material properties of bone tissue, (3). Defective repair of microdamage from normal, daily activities and (4) excessive bone remodeling rates.These factors occur in the context of age-related bone loss. Clinical studies of estrogen deprivation antiresorptives,,, Mechanical loading and disuse, have helped further knowledge of the factors affecting bone quality and the mechanisms that. Underlie them. This progress has led to several new drug targets in the treatment of osteoporosis.

.